What Real-World Data Shows About Current Cancer Care

Late-phase tech transfers bring years of valuable process characterization that sponsors want to protect. In this webinar, Catalent’s Danielle Wittenwyler, PhD, will share how teams can preserve existing process knowledge while translating it into a new manufacturing environment. Learn how a structured, risk-based approach supports seamless transfer, validation readiness, and a strong foundation for continued process verification (CPV).

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/current_care

Event overview:

Oncology care has changed significantly in recent years. Treatment decisions are increasingly shaped by biomarkers, combination and sequencing strategies, and longer patient journeys that extend well beyond initial therapy. While clinical trials remain the gold standard, they do not fully reflect how cancer is treated today across real-world settings.
How is real-world data (RWD) being used today alongside trial evidence? What can high-quality, clinically grounded data reveal about treatment patterns, outcomes, and unmet needs? What limitations still require caution? Panelists will discuss current applications of RWD and evidence across clinical development, trial planning, regulatory and post-approval research, including the growing emphasis on longitudinal data, representativeness, and clinical oversight. Importantly, they will cover how expectations for data quality and governance have evolved as RWD plays a more central role in oncology research and decision-making.

Key Learning Objectives

• Learn how RWD is being used today alongside clinical trials to inform oncology research, not replace it
• Understand where high-quality RWD adds the most value across trial planning, treatment sequencing, and post-approval evidence generation
• Know what “data quality” means in practice, including clinical depth, longitudinal follow-up, and representativeness
• Explore common pitfalls in oncology RWD and how experienced teams assess limitations and bias
• Understand how expectations for RWD have evolved across clinical, research, and decision-making contexts

Who Should Attend

• Clinical Research
• Clinical Development
• Data Science
• Medical Affairs
• Health Economics & Outcomes Research (HEOR)
• Commercialization
• Real World Evidence
• Regulatory
• Oncology

Speakers:

C.K Wang, MD
General Manager of Oncology & Chief Medical Officer
Verana Health

C.K. Wang is the General Manager of Oncology and Chief Medical Officer at Verana Health where he oversees the oncology division and serves as the clinical lead for the company.

C.K. joined Verana Health through a merger with COTA where he served as the Chief Medical Officer for six years and, under his tenure as Chief Executive Officer, finalized COTA's merger with Verana Health. During his time at COTA, C.K. launched the company's research services and helped establish COTA as the premier hematologic oncology real-world solutions provider. Prior to COTA, C.K. served in numerous leadership roles within IBM Watson Health's Oncology and Genomics division supporting clients and partners on a global basis. Before IBM Watson Health, C.K. spent 12+ years in clinical practice where he focused on establishing oncology practices and cancer programs.

C.K. holds a B.A. in Biology from Washington University in St. Louis and received his medical degree from the University of Texas Medical School in San Antonio. He completed his internal medicine residency at the University Hospitals of Cleveland/ Case Western Reserve University and his hematology and oncology fellowship at the University of Texas Southwestern Medical Center. He is board certified in medical oncology.

Ankit Kansagra, MD
Associate Vice President of Oncology Integration and Community Alliance
Tampa General Hospital

Dr. Ankit J. Kansagra, MD is a hematologist-oncologist and physician-scientist currently serving at the TGH Cancer Institute, where he leads Oncology Integration & Community Alignment across for the cancer institute. His career spans academic medicine, global clinical development, and program development. At UT Southwestern Medical Center, he built and led the Outpatient Stem Cell & Cellular Therapy program, founded the nationally recognized Multidisciplinary Amyloidosis Program, and led many RWD data trials for landmark clinical trials, including MAMMOTH — a real-world evidence study that directly influenced FDA drug approvals in multiple myeloma and helped establish contemporary standards for evidence generation in hematologic malignancies.

Prior to joining TGH, Dr. Kansagra served as Senior Medical Leader at Johnson & Johnson's Innovative Medicine, where he led global clinical development programs for novel bispecific immunotherapies, built community oncology research networks to expand trial access, and drove the development of data infrastructure and AI-assisted tools to support clinical decision-making and protocol design. A published author on real-world evidence in hematologic malignancies, Dr. Kansagra has experience in the full continuum — academic research, global drug development, and frontline patient care — bringing a practitioner's clarity to the role of RWD.

Jeff Allen
President & Chief Executive Officer
Friends of Cancer Research

Jeff Allen is President and CEO of Friends of Cancer Research (Friends). Friends is an advocacy organization based in Washington, DC that drives collaboration among partners from every healthcare sector to power advances in science, policy, and regulation that speed life-saving treatments to patients.
Jeff manages a leading non-profit cancer research policy and advocacy organization that focuses on innovative research partnerships and healthcare policy particularly related to the FDA. His responsibilities include creating and implementing research and policy initiatives, organizational governance, coordinating staff for scientific and regulatory programs, fundraising, communications, policy activities, speaking at public symposia, and engaging with congressional leaders, federal officials, and scientific experts. Jeff has helped develop and lead collaborative initiatives aimed to advance and harmonize biomarker development, validate clinical trial endpoints, optimize use of real-world evidence, and establish innovative policies including the Breakthrough Therapy Designation.

Jeff previously worked as an Endocrinology & Immunology Research Fellow at the National Institutes of Health. This involved primary research focused on intracellular signal transduction related to growth regulation and apoptosis. He is also the co-author of over 50 peer-viewed publications in leading medical journals and policy publications and has been called to testify before Congress and contribute expertise to the legislative process on multiple occasions.
Jeff holds a Ph.D. in Cell and Molecular Biology from Georgetown University and a Bachelor of Science from Bowling Green State University.

Donna Rivera
Executive Vice President, Clinical Evidence Modernization
Canal Row Advisors

Donna Rivera, PharmD, MSc, FISPE is the Executive Vice President of Clinical Evidence Modernization at Canal Row Advisors, sharing guidance on the use of real-world data (RWD), real-world evidence (RWE), and artificial intelligence for drugs, biologics, and devices to support regulatory objectives. She was the Founding Director of the Oncology Real-World Evidence Program in the FDA Oncology Center of Excellence, leading national and international initiatives to transform RWD into RWE to accelerate innovation in oncology drug development. She also formed the FDA Oncology AI Program, chairing the Oncology AI Council to guide the use of artificial intelligence applications in regulatory review, research, and policy.

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/current_care